Sintropium bromide

Drug Profile

Sintropium bromide

Alternative Names: VAL 480

Latest Information Update: 23 Dec 2015

Price : $50

At a glance

  • Originator Valeas
  • Class Analgesics
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Dystocia; Spasm

Most Recent Events

  • 18 May 2001 No-Development-Reported for Spasm in Italy (Unknown route)
  • 13 Feb 1997 Preregistration for Spasm in Italy (Unknown route)
  • 25 Oct 1994 Phase-III clinical trials for Spasm in Italy (Unknown route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top